Studies

Increased vascularization and improved tissue repair signaling were observed in animal models.

Participants showed modest reductions in adiposity without major endocrine changes.

Significant reduction in visceral adipose tissue and increase in IGF-1 levels observed.

Participants experienced substantial weight reduction relative to placebo.

Significant reductions in body weight observed across treatment arms.

Marked reductions in body weight were reported in phase 2 trials.

Improved insulin sensitivity and metabolic homeostasis in animal models.

Enhanced collagen synthesis and dermal repair signaling observed.

Observed improvements in neurotrophic signaling and neuronal survival.

Modulation of GABAergic neurotransmission and reduced anxiety behavior observed.

Improved sexual desire scores compared with placebo.

Oxytocin modulates trust, bonding, and social behavior in humans.

IGF-1 signaling activates anabolic pathways involved in muscle growth.

GH influences body composition, metabolism, and tissue repair pathways.

Activation of T-cell mediated immune responses observed.

LL-37 contributes to innate immune defense mechanisms.

Reduction of inflammatory signaling observed.

Increased telomerase activity observed in cell culture studies.

NAD+ restoration linked to improved metabolic function in models.

Robust GH secretion observed after peptide administration.

Stimulated endogenous growth hormone release observed.

Potential involvement in sleep cycle modulation observed.

Study demonstrated modulation of nitric oxide pathways and improved endothelial repair signaling.

Increased endothelial cell motility and enhanced angiogenesis signaling were observed.

Improved cardiac repair and reduced scar formation were observed.

Lipolysis increased without significant endocrine disruption.

MOTS-c improved insulin sensitivity and metabolic resilience in animal models.

The peptide improved glucose tolerance and metabolic regulation.

Increased collagen production and dermal remodeling observed.

Copper peptides stimulate collagen synthesis and tissue regeneration pathways.

Participants achieved substantial weight loss relative to placebo.

Improved glucose regulation and reduced cardiovascular risk markers.

Significant body weight reductions observed in clinical trials.

Improved glycemic control and body weight reduction observed.

Marked reductions in body weight and metabolic improvements observed.

Participants showed major reductions in body weight and improved metabolic markers.

Significant decreases in visceral adipose tissue observed.

Improvements in body composition and metabolic markers reported.

Stimulated pituitary GH secretion observed.

GH regulates metabolism, body composition, and tissue repair.

Improved tendon fibroblast activity and accelerated healing were observed in experimental models.

Topical treatment accelerated wound closure and improved histologic healing.

The review concluded that BPC-157 has broad preclinical healing signals but limited human evidence.

The review noted promising animal data with limited human clinical evidence.

MOTS-c improved insulin sensitivity and reduced obesity-related metabolic dysfunction in mice.

The review positioned MOTS-c as a regulator of obesity, diabetes, exercise, and longevity pathways.

Intermittent MOTS-c treatment improved physical capacity and healthspan markers in mice.

The review summarized evidence for AMPK activation and broader metabolic protective effects.

The review emphasized preclinical promise and lack of established clinical application methods.

Peptides including GHK-Cu were described as regulators of dermal repair and collagen dynamics.

Semaglutide produced sustained weight reduction over extended follow-up in obesity populations.

Semaglutide reduced major adverse cardiovascular events in this population.

Oral semaglutide 25 mg led to greater mean weight reduction than placebo.

Higher-dose semaglutide improved weight outcomes versus placebo in the STEP UP program.

Tirzepatide reduced weight and delayed progression to type 2 diabetes over three years.

Substantial and clinically meaningful body-weight reduction was observed.

Tirzepatide was superior to semaglutide for reduction in body weight and waist circumference at week 72.

The review found robust weight-loss efficacy with expected incretin-class adverse events.

Ipamorelin increased GH release with greater selectivity than earlier secretagogues.

Growth hormone secretagogues were shown to stimulate pulsatile GH secretion through GHS-R pathways.

GHRH analogs can stimulate endogenous GH release while preserving physiologic pituitary control.

Lean mass increased and fat mass decreased with GH replacement therapy.

IGF-I was described as a major mediator of anabolic and metabolic processes.

IGF-I activates anabolic signaling involved in hypertrophy and repair.

Semax increased BDNF-related signaling and improved neuronal survival.

Semax was summarized as a neuroactive peptide with preclinical support and limited broader clinical adoption.

Selank altered genes involved in neurotransmission and stress response pathways.

Selank reduced anxiety-like behavior with evidence of nootropic effects in preclinical testing.

Thymosin alpha 1 enhanced innate and adaptive immune signaling across multiple settings.

The peptide was shown to affect dendritic cells, T cells, and host defense pathways.

LL-37 plays broad roles in antimicrobial activity and immune signaling.

LL-37 can drive both host defense and context-dependent inflammatory signaling.

KPV reduced mucosal injury and inflammatory cytokine signaling.

KPV was described as a candidate anti-inflammatory peptide with preclinical support.

Epitalon influenced telomerase activity and markers related to cellular senescence.

The review highlighted limited but intriguing experimental data on peptide modulation of aging pathways.

NAD+ restoration improved mitochondrial function and tissue regeneration signals.

NAD+ decline was linked to age-related dysfunction across multiple tissues.

Oxytocin influences social behavior in a context-dependent manner rather than uniformly increasing prosociality.

Oxytocin effects were mixed and dependent on dose, task, and population studied.

Bremelanotide improved desire and reduced distress compared with placebo.

The drug was summarized as an on-demand melanocortin agonist with modest but meaningful clinical benefit.

GH fragments were presented as attempts to separate lipolysis from classical GH adverse effects.

The fragment increased lipolysis and reduced fat accretion in preclinical settings.

Adipotide reduced body weight and adiposity by targeting the blood supply of white fat.

The review highlighted proof-of-concept efficacy but translational safety questions.

Hexarelin was described as a potent GHS with endocrine and possible cardioprotective effects.

Hexarelin produced robust GH responses through growth hormone secretagogue pathways.

The review concluded that DSIP has biologic plausibility in sleep regulation but inconsistent replication.

DSIP remained an intriguing but incompletely validated sleep-related peptide.

Sustained increases in GH and IGF-1 were observed after administration.

Long-acting GHRH analogs can meaningfully augment GH/IGF-1 exposure with intermittent dosing.

Growth hormone replacement improved lean mass and reduced fat mass overall.

Tesamorelin increased lean mass and reduced visceral adipose tissue with predictable IGF-1 changes.

The peptide fragment showed some fat-loss signaling with mixed overall clinical efficacy.

Preclinical data were promising but the review emphasized limited human evidence.

Peptide drugs were shown to be a fast-growing pharmaceutical category with improving delivery technology.

The review highlighted endocrine and metabolic peptides as leading clinical success stories.

GLP-1 therapies showed broad metabolic and cardiovascular benefits across trials.

Incretin hormones were shown to regulate appetite, insulin secretion, and glucose metabolism.

Mitochondrial peptides were identified as regulators of metabolic stress adaptation and aging.

Host-defense peptides were shown to integrate direct antimicrobial activity with immunomodulation.

IGF pathways were described as central regulators of anabolic and metabolic responses.

Oxytocin influenced social cognition and bonding-related behavior across human studies.

Oxytocin effects were context-dependent and related to social cue processing.

Treatment improved sexual desire scores compared with placebo.

The drug increased arousal response relative to placebo.

Sermorelin-type stimulation was shown to provoke endogenous GH release.

Growth hormone secretagogues increased GH pulses through GHS-R activity.

The peptide showed experimental associations with sleep modulation.

Peptides were shown to affect extracellular matrix remodeling and skin repair.

Tirzepatide generally achieved greater weight loss, while both agents showed strong efficacy.

Semaglutide, tirzepatide, and next-generation agents were described as reshaping obesity care.

Healing enhancement was linked to fibroblast migration and tendon-repair signaling.

The peptide improved metabolic adaptation to stress in skeletal muscle contexts.

NAD+ was described as central to redox biology, sirtuins, and mitochondrial maintenance.

The review supported immunorestorative effects with heterogeneous clinical evidence.

Results supported serotonergic and stress-modulating effects consistent with anxiolysis.

Results supported neuroprotective and neuromodulatory actions in preclinical models.

Tesamorelin had the strongest modern clinical data, especially for visceral adiposity outcomes.

MK-677 significantly increased GH and IGF-1 levels compared with placebo.

Increased fat-free mass and GH levels but modest metabolic side effects observed.

MK-677 enhanced REM sleep and GH pulsatility.

Increased circulating IGF-1 and improved body composition markers.

Confirmed strong stimulation of GH secretion via GHS-R activation.

Patients lost significantly more weight compared to placebo groups.

Strong appetite suppression observed through monoamine reuptake inhibition.

Consistent weight reduction across trials with dose-dependent effects.

SS-31 reduced mitochondrial damage and improved ATP production.

SS-31 significantly reduced oxidative injury and preserved mitochondrial function.

Improved mitochondrial efficiency and reduced oxidative stress.

Significant enhancement of wound healing and blood vessel formation.

Promoted cardiac cell survival and repair pathways.

Increased melanin production and tanning response observed.

Observed increased sexual arousal responses in study participants.

Increased mitochondrial activity and energy expenditure observed.

Pinealon reduced neuronal degeneration and improved cognitive markers.

Significant improvements in behavioral depression models.

Melanotan compounds strongly activate melanocortin receptors.

Confirmed role in actin binding and cellular migration.

Increased bone formation markers observed.

Tesofensine influences dopamine and serotonin pathways regulating appetite.

Improved mitochondrial respiration and reduced oxidative damage.

Observed central nervous system mediated arousal effects.

Highlighted regenerative and anti-inflammatory mechanisms.

Increased GH secretion and IGF-1 levels confirmed.

Significant increases in mitochondrial respiration observed.

Observed neuroprotective gene expression changes.

Improved behavioral outcomes in depression models.

Increased mitochondrial ATP production and endurance markers.